Validated MCF7 Xenograft Model:
Subcutaneous And Orthotopic Xenograft Tumor Model

By Altogen Labs, 11200 Menchaca Road, Suite 203, Austin, TX 78748
Phone: (512) 433-6177 | Email: info@altogenlabs.com

Innovative Approaches in Breast Cancer Research Using Xenograft Models

Breast cancer remains one of the most prevalent and challenging diseases worldwide, with significant research efforts focused on understanding its complex biology and improving therapeutic outcomes. Xenografts, where human tumor tissue is implanted into immunocompromised mice, have become a vital model for studying breast cancer. These models offer an effective platform for examining the growth, metastasis, and drug response of human tumors in a living organism. By mimicking human breast cancer biology more closely than traditional cell culture models, xenografts provide insights into the tumor microenvironment, immune interactions, and metastatic patterns. Additionally, they are valuable for preclinical drug testing, helping to evaluate the efficacy of novel treatments. Through the use of various breast cancer xenograft models, researchers can better understand the heterogeneity of the disease, leading to the development of more personalized therapeutic strategies. As advancements in molecular biology and biotechnology continue, the role of xenografts in breast cancer research will only expand, contributing to more targeted and effective interventions.

MCF7 Cell Line

The MCF7 cell line was derived in 1970 from a 69-year-old Caucasian woman diagnosed with breast adenocarcinoma. This widely used epithelial cell line is known for expressing key hormone receptors, including estrogen, progesterone, and glucocorticoid receptors, making it a valuable model for studying hormone-responsive breast cancer. MCF7 cells exhibit characteristics of differentiated mammary epithelium, such as the ability to form domes and process estradiol through cytoplasmic estrogen receptors. These features allow MCF7 to mimic the behavior of normal breast tissue in a cancerous context. As the most well-characterized and widely utilized human breast cancer cell line, MCF7 has been instrumental in exploring mechanisms of breast cancer progression, hormone signaling, and drug resistance. Additionally, MCF7 is commonly employed in testing the efficacy of new therapeutic agents, particularly those targeting hormonal pathways. Due to its well-documented properties and reproducibility, MCF7 remains a cornerstone in breast cancer research and drug development.



Figure 1. Tumor Histology. H&E stained slide of subcutaneously-implanted MCF7 tumor (Altogen Labs).

Altogen Labs Validated MCF7 Xenograft Model

In preclinical xenograft studies at Altogen Labs, MMCF7 cells are cultured under conditions that promote exponential growth to ensure consistency in tumor initiation before collection. Prior to injection, the cells are trypsinized, and their viability is assessed using trypan blue exclusion. A minimum cell viability of 98-99% is required to proceed with the *in vivo* study to ensure the reliability of tumor formation. The cell suspension density is carefully adjusted to achieve optimal implantation conditions. To establish tumors, 10- to 12-week-old NOD/SCID mice receive a subcutaneous injection of MCF7 cells into the flank of the hind leg. Each injection consists of 1 million cells suspended in a 100 µL volume of a 50% Matrigel mixture, which provides an extracellular matrix-like environment that facilitates tumor engraftment and growth.



Figure 2. MCF7 breast cancer xenografted in immunocompromised mice, mean values +/- SEM (Altogen Labs).

Once tumors are detectable, the animals are divided into treatment groups based on the treatment schedule. Tumor development is monitored through palpation of the injection site three times per week to determine when tumors become measurable. Tumor size is recorded using digital calipers, and the study formally begins once tumors reach a volume of 100-150 mm³. The animals are then randomized into treatment groups according to the study design and treatment schedule. Tumor growth is measured daily, while mouse body weights are recorded three times per week to assess overall health and treatment-related toxicity. Animals are euthanized when tumors reach a maximum allowable volume of 2,000 mm³ or a predetermined endpoint defined by the approved IACUC protocol. Necropsies are performed according to the study plan, and tumors are excised, weighed, and, if required, digitally imaged for documentation. Additionally, collected tissues can be preserved for downstream molecular or histological analyses. Samples may be snap-frozen in liquid nitrogen for genomic and proteomic studies, submerged in RNAlater reagent for RNA preservation, or fixed and embedded for histological examination, enabling comprehensive evaluation of tumor biology and treatment response.



Figure 3. Tumor weight of MCF7 cells in control group mice and olaparib treated mice at end of the study (Altogen Labs).

Exploring Drug Resistance in Breast Cancer Using Subcutaneous MCF7 Models

The subcutaneous MCF7 model is a widely used preclinical system for studying hormone-responsive breast cancer. In this model, MCF7 cells are implanted beneath the skin of immunocompromised mice, where they form solid tumors that closely resemble the behavior of human breast cancer. This model is particularly valuable for investigating tumor growth, metastasis, and response to therapeutic agents, especially those targeting estrogen receptors. The subcutaneous MCF7 xenograft model offers a reliable platform to assess the effects of anti-hormonal therapies such as tamoxifen and aromatase inhibitors. Additionally, it can be used to explore the mechanisms of drug resistance, as MCF7 cells are known to develop resistance to hormonal treatments over time. Researchers also utilize this model to test novel drug combinations and evaluate the impact of various therapeutic approaches on tumor regression and progression. Due to its reproducibility and the ability to monitor tumor development non-invasively, the subcutaneous MCF7 model remains fundamental in breast cancer research and drug discovery.

Enhancing Breast Cancer Research with Orthotopic MCF7 Xenografts

The orthotopic MCF7 model is an advanced preclinical system used to study estrogen receptor-positive (ER+) breast cancer in a physiologically relevant environment. In this model, MCF7 cells are implanted directly into the mammary fat pad of immunocompromised mice, allowing tumors to develop in their native tissue microenvironment. This approach better recapitulates the architecture, stromal interactions, and hormone responsiveness of human breast tumors compared to subcutaneous models. The orthotopic MCF7 model is particularly valuable for studying tumor progression, hormone-dependent growth, and response to endocrine therapies such as tamoxifen and aromatase inhibitors. Due to the relatively low metastatic potential of MCF7 cells, modifications such as genetic alterations or co-injection with stromal components are sometimes used to enhance invasion and metastasis. Additionally, this model enables investigations into the tumor microenvironment, including interactions with immune cells and the extracellular matrix. The ability to assess tumor behavior in a more biologically relevant setting makes the orthotopic MCF7 model critical in breast cancer research and drug development.

Case Study: Chemo-Endocrine Strategy Targeting ER-Positive MCF7 Breast Cancer Cells

A study conducted by Nukatsuka M, *et al*., published by *In Vivo* journal, explored the combined effects of the oral fluoropyrimidine S-1 and the estrogen receptor (ER) down-regulator fulvestrant on estrogen-responsive breast cancer, with a particular focus on the MCF7 cell line. MCF7, an ER-positive human breast cancer cell line, was used to evaluate cytotoxicity *in vitro* and *in vivo*. The results demonstrated that fulvestrant alone inhibited MCF7 cell growth but had no effect on the ER-negative MDA-MB-231 cells, highlighting its specificity for ER-positive tumors. When combined with 5-fluorouracil (5-FU) *in vitro*, fulvestrant exhibited additive to supra-additive effects in inhibiting MCF7 cell proliferation. *In vivo*, S-1 and fulvestrant showed significantly greater tumor growth suppression in MCF7 xenografts compared to either

monotherapy. Immunohistochemical analysis further revealed that fulvestrant partially downregulated ERα and progesterone receptor (PgR) expression, but in combination with S-1, it nearly abolished their presence. These findings suggest that the combination of S-1 and fulvestrant enhances antitumor efficacy by effectively reducing ERα-mediated signaling. Given that S-1 has a favorable toxicity profile and is an oral agent, this chemo-endocrine combination may provide an effective and convenient therapeutic strategy for postmenopausal patients with ER-positive breast cancer, warranting further clinical investigation.

Additional Case Study: MCF7 Breast Cancer Cells Respond to Continuous CDK4/6 Inhibition with G1T38

In another study by Bisi JE, *et al.*, published by *Oncotarget* journal, researchers investigated the preclinical efficacy of G1T38, a novel and selective CDK4/6 inhibitor, in estrogen receptor-positive (ER+) breast cancer, with a focus on the MCF-7 cell line. MCF-7, a well-characterized ER+ breast cancer model, was used for both *in vitro* and *in vivo* assessments of G1T38's tumor-suppressive effects. The inhibitor demonstrated potent G1 cell cycle arrest and suppressed RB phosphorylation, a key event in CDK4/6-driven cancer proliferation. Compared to palbociclib, the first FDA-approved CDK4/6 inhibitor, G1T38 showed equivalent or superior tumor growth inhibition in MCF-7 xenografts while displaying improved pharmacokinetics, with higher tumor accumulation and reduced systemic exposure. Notably, continuous daily oral dosing of G1T38 was feasible without inducing severe neutropenia, a common adverse effect limiting current CDK4/6 inhibitors. Furthermore, G1T38 significantly enhanced tumor suppression when combined with endocrine therapies such as tamoxifen and fulvestrant, indicating strong synergy in hormone-dependent breast cancer models. The combination of G1T38 with PI3K inhibitors also yielded superior anti-tumor effects, highlighting its potential in overcoming therapy resistance. These findings establish G1T38 as a promising candidate for continuous, well-tolerated CDK4/6 inhibition in ER+ breast cancer, warranting further clinical evaluation.

The MCF-7 Cell Line: Unraveling ER+ Breast Cancer Mechanisms

Unlike more aggressive breast cancer cell lines, MCF-7 cells exhibit low invasive potential, but they retain the ability to proliferate in response to estrogen stimulation. Due to their hormone sensitivity, MCF-7 cells are extensively used to evaluate the efficacy of endocrine therapies, including tamoxifen and fulvestrant, as well as novel CDK4/6 inhibitors. Additionally, these cells have been instrumental in studying the effects of environmental factors, such as alcohol exposure, on breast cancer progression, demonstrating ethanol-induced changes in gene expression, oncogenic markers, and stemness-related proteins. The ability of MCF-7 cells to form mammospheres also provides insight into cancer stem cell biology, helping researchers explore mechanisms of drug resistance and tumor recurrence.

Lipid Regulation and Hormone Sensitivity in MCF-7 Breast Cancer Cells

MCF-7 is a widely used luminal A breast cancer cell line that expresses estrogen (ER) and progesterone receptors (PgR), making it a valuable model for studying hormone-responsive tumors. Unlike HER2-positive and triple-negative breast cancer cell lines, MCF-7 exhibits a distinct dependency on lipid metabolism, particularly cholesterol levels, which significantly impact its growth, proliferation, and gene expression. Studies have shown that cholesterol depletion reduces MCF-7 cell proliferation, downregulating Ki67, a marker of cellular proliferation, while simultaneously increasing ER and PgR expression. In contrast, high cholesterol levels enhance cell growth and suppress tumor-suppressive pathways, such as PTEN and CDKN1A. Additionally, cholesterol influences sphingomyelin metabolism, which is critical for maintaining membrane integrity and cell signaling, further affecting tumor progression. The modulation of cholesterol levels alters the expression of key regulatory enzymes, such as HMG-CoA reductase, which is upregulated under cholesterol-depleted conditions. These findings suggest that cholesterol plays a crucial role in breast cancer metabolism, therapeutic response, and potential drug resistance, highlighting the importance of lipid regulation in developing targeted cancer therapies.

Patient-Derived Tumor Organoids: Advancing Cancer Research

Organoids are 3D *in vitro* tumor cultures derived from patient samples, replicating the genetic, phenotypic, and structural complexity of the original cancer. Unlike traditional 2D cell cultures, organoids retain tissue heterogeneity and can be efficiently expanded from primary patient material, making them valuable for personalized oncology and drug discovery. While xenograft and allograft models provide insights into tumor-stroma and immune interactions, organoids offer a faster, scalable platform for testing therapeutic responses. Advances in organoid technology have enabled the creation of patient-derived tumor organoid (PDTO) biobanks, essential for studying cancer progression, drug resistance, and personalized treatment strategies. These models excel in high-throughput drug screening, helping to identify targeted therapies based on a tumor's molecular profile.

Immuno-oncology Xenograft Models

Altogen Labs is a leading preclinical research organization specializing in the evaluation of novel pharmacological and biological therapies, including anticancer treatments, medical compounds, vaccines, cosmetics, and natural products. With a team of expert scientists, the company provides laboratory services, employing the latest technologies to advance oncology research and accelerate drug development. Altogen Labs offers specialized immuno-oncology services, utilizing humanized and immunodeficient rodent models engrafted with peripheral blood mononuclear cells (PBMC), CD34+ hematopoietic stem cells, and induced pluripotent stem cells (iPSC) to study immune responses, drug efficacy, and toxicity. A key strength of Altogen Labs is its extensive collection of over 100 in-house validated xenograft models, including CDX, patient-derived xenografts (PDX), *in vitro* patient-derived cell cultures (PDC), and patient-derived organoids (PDOrg), providing clinically relevant platforms for predicting drug efficacy. The company also conducts comprehensive toxicity studies, evaluating acute, sub-chronic, and chronic toxic effects to ensure compound safety and long-term tolerability.



Figure 4. Advanced immune-oncology services available at Altogen Labs (Altogen Labs).

Altogen Labs offers a wide range of preclinical research services, with a strong focus on *in vivo* tumor models, including the well-established MCF7 xenograft model for estrogen receptor-positive (ER+) breast cancer research. Conducted in GLP-compliant, IACUC-regulated facilities, these studies enable precise evaluation of tumor progression, drug efficacy, and treatment response. Researchers can customize their studies with various experimental parameters, ensuring data quality and relevance to therapeutic development. Altogen Labs provides a wide range of preclinical research services, including pharmacology and toxicology testing, *in vivo* anti-tumor activity assessments, and RNA interference (RNAi) studies. Additional capabilities include liposome encapsulation for nucleic acid delivery, ELISA and cell-based assay development, and the generation of stable cell lines within 28 days. As a contract research organization (CRO), Altogen Labs specializes in *in vivo* toxicology studies, gene expression analysis via RT-PCR, and the development of RNAi-based gene knockdown models. The company also offers GLP-compliant cell banking services, including cryopreservation and master cell bank generation.



Figure 5. *In vivo* xenograft services offered at Altogen Labs for MCF7 (Altogen Labs).

To support diverse research needs, Altogen Labs provides multiple study options for the MCF7 xenograft model. These include tumor growth delay (TGD) and tumor growth inhibition (TGI) assessments, as well as flexible dosing strategies via intravenous, intraperitoneal, intratumoral, oral, and subcutaneous routes. Alternative cell engraftment methods, such as orthotopic transplantation, tail vein injection, and left ventricular injection for metastasis studies, are also available. Additional services include tumor immunohistochemistry, blood chemistry analysis, lipid distribution studies, metabolic assays, and fluorescence-based imaging for real-time tumor monitoring. Comprehensive necropsy and histopathology services allow for detailed tissue analysis, while positive control groups treated with clinically validated agents like cyclophosphamide provide reference data for treatment efficacy comparisons. These customizable options enable in-depth exploration of breast cancer biology and therapeutic responses using the MCF7 xenograft model.

References:

Albi E, Mandarano M, Cataldi S, Ceccarini MR, Fiorani F, Beccari T, Sidoni A, Codini M. The Effect of Cholesterol in MCF7 Human Breast Cancer Cells. *Int J Mol Sci.* 2023 Mar 21;24(6):5935. doi: 10.3390/ijms24065935. PMID: 36983016; PMCID: PMC10052157.

Bisi JE, Sorrentino JA, Jordan JL, Darr DD, Roberts PJ, Tavares FX, Strum JC. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors. *Oncotarget*. 2017 Jun 27;8(26):42343-42358. doi: 10.18632/oncotarget.16216. PMID: 28418845; PMCID: PMC5522071.

Gelfand R, Vernet D, Bruhn KW, Sarkissyan S, Heber D, Vadgama JV, Gonzalez-Cadavid NF. Long-term exposure of MCF-7 breast cancer cells to ethanol stimulates oncogenic features. *Int J Oncol.* 2017 Jan;50(1):49-65. doi: 10.3892/ijo.2016.3800. Epub 2016 Dec 9. PMID: 27959387; PMCID: PMC5182011.

Nukatsuka M, Saito H, Noguchi S, Takechi T. Estrogen Down-regulator Fulvestrant Potentiates Antitumor Activity of Fluoropyrimidine in Estrogen-responsive MCF7 Human Breast Cancer Cells. *In Vivo*. 2019 Sep-Oct;33(5):1439-1445. doi: 10.21873/invivo.11622. PMID: 31471390; PMCID: PMC6754987.

Xu L, Du J, Wan C, Zhang Y, Xie S, Li H, Yang H, Li F. Ultrasound molecular imaging of breast cancer in MCF7 orthotopic mice using gold nanoshelled poly(lactic-co-glycolic acid) nanocapsules: a novel dual-targeted ultrasound contrast agent. Int J Nanomedicine. 2018 Mar 21;13:1791-1807. doi: 10.2147/IJN.S153993. PMID: 29606871; PMCID: PMC5868579.

Keywords: MCF7, breast cancer, xenograft, breast, *in vivo*, cancer, preclinical, research, *in vivo* pharmacology, orthotopic, CDX, PDX, organoids

Other Available Altogen Labs Validated Xenograft Models:

BT474 Xenograft Model: https://altogenlabs.com/xenograft-models/breast-cancer-xenograft/bt474-xenograft-model/

Hs578T Xenograft Model: https://altogenlabs.com/xenograft-models/breast-cancer-xenograft/hs578t-xenograft-model/

MCF7 Xenograft Model: https://altogenlabs.com/xenograft-models/breast-cancer-xenograft/mcf7-xenograft-model/

HCC1954 Xenograft Model: https://altogenlabs.com/xenograft-models/breast-cancer-xenograft/hcc1954-xenograft-model/

NCI-H460 Xenograft Model: https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/h460-xenograft-model/

NCI-H1975 Xenograft Model: https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/nci-h1975-xenograft-model/

NCI-H226 Xenograft Model: https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/nci-h226-xenograft-model/

NCI-H1155 Xenograft Model: https://altogenlabs.com/xenograft-models/lung-cancer-xenograft/h1155-xenograft-model/